Home  »  Markets Briefing   »  The Fundamental Case for and Against Sage Therapeu...

The Fundamental Case for and Against Sage Therapeutics (SAGE)

During the past 52 weeks, Sage Therapeutics (SAGE) shares have fallen about 25%. Another reason for the decline in quotations is the drug’s inability to treat depressive disorders in trials. There are other developments in the Sage Therapeutics that has commercial potential.

The FDA approved brexanolone by Sage Therapeutics in March of last year. This is the only approved treatment for postpartum depression and the first of its kind. SAGE-217, the drug used to treat depression, failed in clinical trials, so its stock dropped, and the SAGE stock’s shares fell, too.

Nonetheless, Sage Therapeutics (SAGE) is conducting various other types of research in addition to this one. Sage Therapeutics anticipates the results of a dozen tests this year. This includes plans to publish studies comparing the efficacy of SAGE-217 to other treatments like SAGE-324 for essential tremors and SAGE-718 for Alzheimer’s disease and Parkinson’s disease.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



These testing funds were obtained through a partnership with Biogen (NASDAQ: BIIB ) in November 2020. Both companies agreed to split their SAGE-217 sales equally in the US. A tiered royalty structure will also apply to Sage Therapeutics’ worldwide sales. There has already been an $ 875 million advance payment and $ 650 million in equity investments made to the SAGE stock, along with potential milestones of $ 1.6 billion.

Sage Therapeutics now treats postpartum depression mainly with its drug. The SAGE stock notes that more than 18 million Americans suffer from major depressive disorder and postpartum depression every year. A total of 450 million consumers worldwide are estimated to be a part of its current sales market. Sage Therapeutics’ could be supported in the long run by an impressive drug portfolio.

On 03/24/21, Sage Therapeutics (SAGE) started the day at $70.81, with a -4.00% decrease in price. Stocks rose to $75.14 and sunk to $70.66 during the day before closing at $70.81. Taking a long-term view, SAGE posted a 52-week range of $25.82-$98.39.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

Sign up for Our Newsletter Now! Discover which stocks to trade!
100% Free. Stop Anytime. No Spam